Evidence map›Paper›PMID 21567378›Full record

ArticleArthritis and rheumatism2011

Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients.

Omri Snir, Mary Rieck, John A Gebe, Betty B Yue, Crystal A Rawlings, Gerald Nepom, Vivianne Malmström, Jane H Buckner

Open access · greenAbstract read
In one paragraph

Article in Arthritis and rheumatism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Citrulline immunity in RA: CD8Nature reviews. Rheumatology · 2023
    Article
  15. Review
  16. Article
  17. Cytotoxic CD8Nature communications · 2023
    Article
  18. Article
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Omri SnirRheumatology Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Mary Rieck
John A Gebe
Betty B Yue
Crystal A Rawlings
Gerald Nepom
Vivianne Malmström
Jane H Buckner
Benaroya Research InstituteVirginia Mason Medical Center · USKarolinska Institutet · SE

Funding

Virginia Mason/UCHSC Autoimmune Prevention CenterU19AI050864 · NIAID · UNIVERSITY OF COLORADO DENVER · PI EISENBARTH, GEORGE S · 2001 to 2011
$29.2M
RA-Related Autoantibodies in Healthy FDR of RA PatientsR01AR051394 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI NORRIS, JILL M · 2005 to 2011
$3.0M
HLA SUSCEPTIBILITY GENES IN RHEUMATOID ARTHRITIS (RA)R01AR037296 · NIAMS · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI NEPOM, GERALD T · 1986 to 2009
$2.9M
NIAID NIH HHS 5-U19-AI-050864NIAID NIH HHS U19 AI050864NIAMS NIH HHS 5-R01-AR-037296NIAMS NIH HHS R01 AR037296NIAMS NIH HHS R01 AR051394NIAMS NIH HHS R01-AR-051394
6 · The paper itself

Abstract

objectiveAntibodies toward the citrullinated form of the synovial antigen vimentin are specific for rheumatoid arthritis (RA) and are associated with HLA-DRB1*0401. This suggests that T cells specific for peptides derived from citrullinated vimentin presented in the context of HLA-DRB1*0401 may contribute to the etiopathogenesis of RA. The aim of this study was to identify immunodominant epitopes from citrullinated vimentin presented by HLA-DRB1*0401 and to characterize the resulting T cell responses.

methodsWe first predicted an HLA-binding T cell epitope from citrullinated vimentin based on the binding motif of HLA-DRB1*0401 and then confirmed its affinity. A class II major histocompatibility complex (MHC) tetramer loaded with the citrullinated form of vimentin aa 59-78 (cit-vimentin aa 59-78) was constructed and used to screen for specific T cells in HLA-DRB1*0401-transgenic mice, patients with RA, and healthy control subjects. Additionally, the cytokine output following cit-vimentin aa 59-78 challenge was analyzed in patients and healthy control subjects by multicolor flow cytometry and Luminex-based analysis.

resultsThe citrullinated form of vimentin aa 59-78 bound to HLA-DRB1*0401, but the native form could not. Subsequently, cit-vimentin aa 59-78-specific T cells were detected in immunized mice and in the periphery of both HLA-DR*0401-positive healthy control subjects and HLA-DR*0401-positive patients with RA, using class II MHC tetramers, CD154 up-regulation, and intracellular cytokine measurements. As demonstrated in cell culture supernatants, the production of cytokines (predominantly interferon-γ) in response to cit-vimentin aa 59-78 was significantly higher in patients compared with controls.

conclusionHere, we describe a posttranslational modification of an RA candidate autoantigen toward which HLA-DRB1*0401-restricted T cells can be detected in both patients with RA and healthy controls but for which a proinflammatory response is observed uniquely in patients with RA.

Indexed as

AdultAnimalsArthritis, RheumatoidEpitopes, T-LymphocyteHLA-DRB1 ChainsHumansMiceMice, TransgenicPeptides, CyclicT-LymphocytesVimentinEpitopes, T-LymphocyteHLA-DRB1*04:01 antigenHLA-DRB1 ChainsPeptides, CyclicVimentin

Identifiers

PMID21567378
PMCPMC3174345
OpenAlexW2134293530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.